Format

Send to

Choose Destination
Int Immunol. 2016 Aug;28(8):373-82. doi: 10.1093/intimm/dxw021. Epub 2016 Apr 27.

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.

Author information

1
Laboratory of Integrative Cancer Immunology, INSERM UMRS1138, Cordeliers Research Center, 15 Rue de l'Ecole de Medecine, 75006 Paris, France University Paris Descartes, 45 Rue Saints Pères, 75006 Paris, France Centre de Recherche des Cordeliers, University Pierre et Marie Curie Paris 6, 15 Rue de l'Ecole de Medecine, 75006 Paris, France Immunomonitoring Platform, Laboratory of Immunology, Georges Pompidou European Hospital, 20-40 Rue Leblanc, 75015 Paris, France.
2
Laboratory of Integrative Cancer Immunology, INSERM UMRS1138, Cordeliers Research Center, 15 Rue de l'Ecole de Medecine, 75006 Paris, France Immunomonitoring Platform, Laboratory of Immunology, Georges Pompidou European Hospital, 20-40 Rue Leblanc, 75015 Paris, France.
3
Laboratory of Integrative Cancer Immunology, INSERM UMRS1138, Cordeliers Research Center, 15 Rue de l'Ecole de Medecine, 75006 Paris, France University Paris Descartes, 45 Rue Saints Pères, 75006 Paris, France Centre de Recherche des Cordeliers, University Pierre et Marie Curie Paris 6, 15 Rue de l'Ecole de Medecine, 75006 Paris, France.
4
Laboratory of Integrative Cancer Immunology, INSERM UMRS1138, Cordeliers Research Center, 15 Rue de l'Ecole de Medecine, 75006 Paris, France University Paris Descartes, 45 Rue Saints Pères, 75006 Paris, France Centre de Recherche des Cordeliers, University Pierre et Marie Curie Paris 6, 15 Rue de l'Ecole de Medecine, 75006 Paris, France Immunomonitoring Platform, Laboratory of Immunology, Georges Pompidou European Hospital, 20-40 Rue Leblanc, 75015 Paris, France franck.pages@aphp.fr.

Abstract

The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) tumor, nodes, metastasis (TNM) classification system based on tumor features is used for prognosis estimation and treatment recommendations in most cancers. However, the clinical outcome can vary significantly among patients within the same tumor stage and TNM classification does not predict response to therapy. Therefore, many efforts have been focused on the identification of new markers. Multiple tumor cell-based approaches have been proposed but very few have been translated into the clinic. The recent demonstration of the essential role of the immune system in tumor progression has allowed great advances in the understanding of this complex disease and in the design of novel therapies. The analysis of the immune infiltrate by imaging techniques in large patient cohorts highlighted the prognostic impact of the in situ immune cell infiltrate in tumors. Moreover, the characterization of the immune infiltrates (e.g. type, density, distribution within the tumor, phenotype, activation status) in patients treated with checkpoint-blockade strategies could provide information to predict the disease outcome. In colorectal cancer, we have developed a prognostic score ('Immunoscore') that takes into account the distribution of the density of both CD3(+) lymphocytes and CD8(+) cytotoxic T cells in the tumor core and the invasive margin that could outperform TNM staging. Currently, an international retrospective study is under way to validate the Immunoscore prognostic performance in patients with colon cancer. The use of Immunoscore in clinical practice could improve the patients' prognostic assessment and therapeutic management.

KEYWORDS:

T cells; colorectal cancer; immune response; lymphocyte; tumor microenvironment

PMID:
27121213
PMCID:
PMC4986234
DOI:
10.1093/intimm/dxw021
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center